Xenolith Medical

Company Overview

Snapshot

Founded in July 2010 by Shaul Shohat and Ido Kilemnik, Xenolith Medical operated with 1–10 employees. The company secured funding across one round from Xenia Venture Capital and Virginia Life Sciences Investments (VLSI). In February 2018, Xenolith Medical ceased operations.

Business overview

Xenolith Medical specializes in adapting angioplasty retention and navigation technologies for endourology, focusing on preventing stone fragment migration during ureteroscopic lithotripsy. Its flagship product, the XenX, features a self-expandable braided mesh with a high expansion ratio, allowing for slender insertion and expansion within the ureter. The company leverages advanced wire technologies, including hydrophilic coating and kink-resistant materials, to enhance navigation and maneuverability past occluding stones. Xenolith Medical operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers in Europe and the United States.

Strategic signal

In January 2011, Xenolith Medical secured investment from Xenia Venture Capital and Virginia Life Sciences Investments (VLSI). This early funding validated the company's innovative approach to endourology, signaling investor confidence in its angioplasty retention and navigation technologies for medical applications.

Company Intelligence Q&A

What is Xenolith Medical's primary product?

Xenolith Medical's primary product is the XenX, a device designed to prevent the migration of stone fragments during ureteroscopic lithotripsy procedures.

When was Xenolith Medical founded?

Xenolith Medical was founded in July 2010.

Who are the founders of Xenolith Medical?

Xenolith Medical was co-founded by Shaul Shohat and Ido Kilemnik.

What was the operational status of Xenolith Medical?

Xenolith Medical ceased to operate in February 2018.

Which investors participated in Xenolith Medical's funding round?

In January 2011, Xenolith Medical received investment from Xenia Venture Capital and Virginia Life Sciences Investments (VLSI).